Stockscreener 앱 받기
2.31
0.43%
-0.010
시간 외 거래:
2.25
-0.06
-2.60%
전일 마감가:
$2.32
열려 있는:
$2.34
하루 거래량:
33,682
Relative Volume:
0.15
시가총액:
$93.55M
수익:
$2.70M
순이익/손실:
$5.53M
주가수익비율:
21.00
EPS:
0.11
순현금흐름:
$-10.55M
1주 성능:
+3.12%
1개월 성능:
+10.00%
6개월 성능:
-1.70%
1년 성능:
-1.70%
1일 변동 폭
$2.28
$2.3427
1주일 범위
$2.23
$2.35
52주 변동 폭
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.31 | 93.55M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Press Release Distribution & PR Platform - ACCESS Newswire
ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
What To Expect From Tesla’s (TSLA) Q1 Earnings - The Globe and Mail
Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia
Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
ORMP stock touches 52-week low at $2 amid market challenges - Investing.com
Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter
OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia
Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat
OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India
Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga
Congress Trade: Representative Brad Knott Just Disclosed New Stock Trades - Quiver Quantitative
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat
227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat
Oramed announces spinoff of protein drug technology - MSN
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks
Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph
OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com
Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma
Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha
Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire
Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):